Suchergebnisse - Dual incretin agonists

1

Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?

von: Müller, Timo D.

2023, in: Gynäkologische Endokrinologie

Wird geladen...
2

Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?

von: Müller, Timo D.

2023, in: Der Internist

Wird geladen...
3

Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?

von: Genchi, V. A.

2023, in: Journal of endocrinological investigation

Wird geladen...
4

Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease

von: Salles, Geisa Nogueira

2020transfer abstract, in: Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes

Wird geladen...
5

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

von: Gutgesell, Robert M.

2024, in: Diabetes therapy

Wird geladen...
6

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists

von: Tomislav Bulum

2022, in: Biomedicines

Wird geladen...
7

A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis – Study design and rationale of HM-TRIA-201 study

von: Abdelmalek, Manal F.

2023, in: Contemporary clinical trials

Wird geladen...
8

Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

von: Qingyue Zeng

2024, in: Frontiers in Endocrinology

Wird geladen...
9

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

von: Qingyue Zeng

2023, in: Frontiers in Endocrinology

Wird geladen...
10

Dose–response effects on $ HbA_{1c} $ and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

von: Blüher, Matthias

2023, in: Diabetologia

Wird geladen...
11

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity

von: Baptist Gallwitz

2022, in: Frontiers in Endocrinology

Wird geladen...
12

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review

von: Alexandros Leonidas Liarakos

2023, in: Biomedicines

Wird geladen...
13

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect

von: Enrique Z. Fisman

2021, in: Cardiovascular Diabetology

Wird geladen...

Nicht das Richtige dabei?

Schreiben Sie uns!